Risperidone Articles
FDA receives NDA for J&J paliperidone
12 December 2005
CORRECTION: Janssen's Risperdal
22 August 2005
Janssen's Risperdal: long-term QOL benefits
15 August 2005
Japan stock market week to July 18
25 July 2005
Akzo Nobel net up 22% on 6% sales growth
25 July 2005
Positive results for AstraZeneca's Seroquel
30 May 2005
Bentley gets OK for risperidone in Spain
9 May 2005
Corcept's Corlux shows good weight loss result
25 April 2005
J&J's 17% 1st-qtr earnings rise beats analysts' expectations; firm to buy Peninsula Pharma
25 April 2005
1st-qtr net doubles for Akzo Nobel
25 April 2005
Organon/J&J end Risperdal co-promotion
11 April 2005
Australian PBS new Rx listings aimed at seniors
11 April 2005
Alkermes cuts 3rd-qtr loss
14 February 2005
Australia backtracks on 12.5% generic price cut
14 February 2005
J&J's 4th-qtr net earnings plunge 34%
31 January 2005
Alkermes expands Risperdal Consta capacity
17 January 2005
Benefits of long-term Zyprexa therapy
20 December 2004
Alkermes narrows net loss for 2nd qtr
15 November 2004
Israel: complaints over funds' drug access
23 August 2004
J&J's sales leap 17.7% for 1st-qtr 2004
19 April 2004
Risperdal Consta switch benefits young adults
23 February 2004
J&J 4th-qtr EPS up 35%, sales rise 20%
26 January 2004
Risperdal Consta available in USA
15 December 2003
J&J's Risperdal cleared by FDA for BD
15 December 2003
Litigation fears hit off-label CNS Rxing
15 December 2003
Canadian Rx prices "33%-80% less than in USA"
17 November 2003
Risperdal Consta cleared by FDA
10 November 2003
J&J raises forecast on strong 3rd quarter
20 October 2003
Risperdal Consta cleared in France
20 October 2003
Positive new data for J&J's Risperdal
29 September 2003
Positive results with AstraZeneca Seroquel
29 September 2003
Lilly receives product labeling letter from FDA
29 September 2003
Acquisition charges hit J&J 2nd-qtr results
21 July 2003
J&J launches Risperdal M-Tab in USA
12 May 2003
J&J files Risperdal Consta new data with FDA
5 May 2003
Risperdal Consta approved in UK
10 March 2003
First launch of J&J's Risperdal Consta in UK
19 August 2002
Zyprexa - placebo-like levels of EPS
19 August 2002
Schizophrenia drug Risperdal may treat autism in children
12 August 2002
J&J's Risperdal Consta approved in Germany
12 August 2002
Alkermes posts increased loss of $61M for 2002
8 July 2002
Stock Commentary - New York
8 July 2002
Risperdal Consta not approvable, says FDA
8 July 2002
J&J earnings climb 18.2% in 1st qtr
22 April 2002
J&J hopes to launch cladribine in Japan
8 April 2002
Risperdal cleared to delay relapse in USA
25 March 2002
Risperdal Consta safe and effective as oral
4 March 2002
J&J posts healthy increase in sales and earnings for 2001
28 January 2002
Risperidone study published in NEJM
14 January 2002
Long-acting Risperdal equivalent to oral form
7 January 2002
Long-acting Risperdal equivalent to oral form
14 December 2001
Seroquel compliance tops competitors
12 November 2001
Alkermes expands facility to produce long-acting Risperdal
1 November 2001
Correction: J&J's Risperdal
20 September 2001
J&J files for depot form of Risperdal
6 September 2001
Seroquel outdoes Risperdal on safety, says study
5 July 2001
Georgia's unique Medicaid Rx moves
3 July 2001
Risperdal effective in depot formulation
8 May 2001
B-MS to file NDA for Abilitat in 4th quarter
27 April 2001
J&J beats forecasts with 14% EPS rise
18 April 2001
Depot Risperdal nears US filing
22 February 2001
Stock Commentary - New York
15 February 2001
Pfizer's antipsychotic ziprasidone gets approval in USA
7 February 2001
J&J sales up despite Propulsid problem
24 January 2001
AstraZeneca's Seroquel approved in Japan
14 December 2000
Johnson & Johnson earnings climb 14%
18 October 2000
Risperdal oral solution an option for psychotic crises
14 September 2000
J&J beats forecasts with 2nd qtr earnings
20 July 2000
Stock Commentary Tokyo
15 June 2000
Johnson & Johnson net earnings rise 15.5%
19 April 2000
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
